Articles written by Meg Flippin - Benzinga

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Sponsored

How Jupiter Neuroscience's Two-Prong Approach Could Crack The Code On Biotech Success

Sponsored

How TNL Mediagene Is Leveraging Acquisitions And Organic Growth To Become The Largest Media Tech Company In Southeast Asia

Sponsored

Armed With Donation From Trial Participant's Family, Cognition (Nasdaq: CGTX) Initiates Expanded Access Program For Experimental DLB Drug

Sponsored

Kamada Q1 Results: Double-Digit Growth, Company Reiterates Guidance As It Hits Multiple Milestones Including Plasma Business Expansion

Sponsored

Q1 Earnings: Seanergy Beats Topline And Bottomline Analyst Estimates, Both SHIP And Spin-Off USEA Declare Dividends

Sponsored

The Journey Continues: Pasofino Back On Track To Production After Raising $3.6 Million In A Private Placement To Advance Its Dugbe Gold Project

Sponsored

Kamada Wants To Do More For Organ Transplant Patients, Increases Efforts To Build Awareness Of Its CMV Treatment CYTOGAM

Sponsored

How This Subprime Auto Lender With 55 Straight Quarters Of Profit Is Standing Out From The Pack

Sponsored

LogicMark's Holistic Approach: Leveraging Artificial Intelligence And SaaS To Protect Aging Loved Ones

Sponsored

Watch Out Canada Goose And Moncler – Perfect Moment May Be The Trending Skiwear Brand To Watch

Sponsored

Pushing The Boundaries Of Innovation: How Sportradar Is Setting New Industry Standards

Sponsored

Upcoming Benzinga Webinar With Glucotrack To Discuss The Potential Of Its Innovative CBGM Technology To Transform Diabetes Care And Patient Lives

Sponsored

Lottery.com Expands Into Concerts And Niche Live Events With DotCom Ventures Acquisition

Sponsored

Ascent Solar Inks Deal With NOVI As Its Space Business Takes Off

Sponsored

SeaStar Q1 Results: QUELIMMUNE Sales Up Fourfold Sequentially, Company Now Targeting Adult Market

Sponsored

TNL Mediagene Getting Noticed On Wall Street: Benchmark Equity Research Starts Coverage With Speculative Buy, $3.50 Per Share Price Target

Sponsored

Connected Vehicles Are Leaping Into The Driver's Lane, And Iteris' Software And Hardware Stack Is Playing A Role

Sponsored

Indaptus Therapeutics Q1 Update: Company Advances Decoy20 Immunotherapy To Fight Cancer, Maxim Group Analyst Reiterates Buy Rating

Sponsored

Mining For Gold In Africa: Pasofino Gold Shares Progress On Its 400 Million Ounce Gold Project

Sponsored